Drug Type Antibody drug conjugate (ADC) |
Synonyms GQ 1005, GQ-1005, GQ1005 |
Target |
Mechanism HER2 modulators(Receptor protein-tyrosine kinase erbB-2 modulators) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
HER2 Positive Solid Tumors | Phase 1 | CN | 23 Nov 2022 | |
Breast Cancer | Preclinical | CN | 25 Feb 2022 | |
Stomach Cancer | Preclinical | CN | 25 Feb 2022 |
NCT06154343 (AACR2024) Manual | Phase 1 | Solid tumor HER2 Positive | HER2 Expression | 46 | ltpiqiutex(kocdxwlhip) = deadjtnsld mbimmnajvv (ovmhqlsbvc ) View more | Positive | 05 Apr 2024 | |
NCT06154343 (AACR2024) Manual | Phase 1 | 46 | jccnymaamo(ypnpiimubm) = bbaupkdtpx zhiikbyuhq (ssooogvzjx ) View more | Positive | 05 Apr 2024 |